Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide …

Per the FDA, dosing in all clinical studies of rusfertide may be resumed. … The call will be available to investors, members of the news media, …

By |2021-10-11T11:49:06+00:00October 11th, 2021|Uncategorized|0 Comments

About the Author:

Related Posts

Incyte fails to win FDA nod for cancer therapy (INCY:NASDAQ) | Seeking Alpha
Incyte fails to win FDA nod for cancer therapy (INCY:NASDAQ) | Seeking Alpha
US Customs and Border Protection official says new process for tariff refunds could be ready …
US Customs and Border Protection official says new process for tariff refunds could be ready …
FDA’s Controversial Vaccine Chief Is Leaving the Agency … Again – MedPage Today
FDA’s Controversial Vaccine Chief Is Leaving the Agency … Again – MedPage Today
FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
US Tells Tariff Refund Judge It Can’t Comply With Order – Bloomberg
US Tells Tariff Refund Judge It Can’t Comply With Order – Bloomberg